BROWN'S PHARMA HOLDINGS PLC financials
BROWN'S PHARMA HOLDINGS PLC
391200EUISAEF39QR618 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €50.1M | €38.3M |
| Cost of sales | €33.9M | €24.7M |
| Gross profit | €16.2M | €13.6M |
| Other income | €344.0K | €249.7K |
| Distribution costs | €951.1K | €733.9K |
| Administrative expenses | €10.9M | €9.1M |
| Operating profit (EBIT) | €4.6M | €4.0M |
| Finance costs | €1.4M | €1.2M |
| Profit before tax | €3.3M | €2.8M |
| Income tax expense | €1.1M | €1.3M |
| Profit for the year | €2.2M | €1.6M |
| Total comprehensive income | €13.2M | €1.6M |
| Cash flow statement | ||
| Cash generated from operations | €11.3M | €6.8M |
| Net cash from operating activities | €10.6M | €6.4M |
| Income taxes paid | €757.9K | €663.7K |
| Net cash from investing activities | -€5.5M | -€2.5M |
| Purchase of PP&E (capex) | €1.1M | €712.2K |
| Purchase of intangibles | €4.6M | €1.6M |
| Net cash from financing activities | -€5.5M | -€3.7M |
| Dividends paid | €1.4M | €676.3K |
| Proceeds from borrowings | €3.0M | €2.4M |
| Repayments of borrowings | €672.3K | €251.6K |
| Lease liability payments | €1.3M | €1.1M |
| Balance sheet | ||
| Total assets | €99.7M | €76.3M |
| Non-current assets | €85.9M | €62.8M |
| Property, plant & equipment | €3.1M | €2.8M |
| Right-of-use assets | €10.3M | €9.7M |
| Intangible assets & goodwill | €3.9M | €3.9M |
| Current assets | €13.8M | €13.4M |
| Inventories | €4.2M | €3.5M |
| Trade & other receivables | €5.8M | €5.8M |
| Cash & equivalents | €2.6M | €2.9M |
| Total equity | €38.2M | €26.8M |
| Non-current liabilities | €48.2M | €38.5M |
| Long-term borrowings | €17.3M | €15.0M |
| Lease liabilities (non-current) | €10.2M | €9.5M |
| Current liabilities | €13.3M | €10.9M |
| Lease liabilities (current) | €675.2K | €561.9K |
| Trade & other payables | €12.1M | €10.2M |
| Deferred tax liabilities | €20.7M | €14.1M |
| Derived metrics | ||
| Free cash flow | €9.6M | €5.7M |
| Operating margin | 9.3% | 10.5% |
| Net margin | 4.4% | 4.1% |
| Return on equity | 5.8% | 5.9% |
| Cash conversion ratio | 4.82× | 4.08× |
| Capex coverage | 9.81× | 9.01× |
| Other reported items | ||
| Current Borrowings and Current Portion of Noncurrent Borrowings | €530.1K | €185.5K |
| Current Financial Assets At Amortised Cost | €1.2M | €1.0M |
| Current Tax Assets Current | €95.1K | €174.4K |
| Deferred Tax Assets | €378.3K | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€25.0K | €5.9K |
| Equity and Liabilities | €99.7M | €76.3M |
| Finance Income | €145.8K | €16.4K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €5.9M | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €72.1K | €272.6K |
| Increase Decrease In Cash and Cash Equivalents | -€343.9K | €253.8K |
| Increase Decrease Through Acquisition of Subsidiary | — | €10.1K |
| Increase Decrease Through Transfers and Other Changes Equity | €18.9K | €5.9K |
| Intangible Assets Other Than Goodwill | €68.2M | €46.2M |
| Investments In Subsidiaries | €0 | €0 |
| Issued Capital | €20.1M | €20.1M |
| Liabilities | €61.6M | €49.5M |
| Noncurrent Receivables | €0 | €0 |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | €304.0K | €1.1M |
| Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities | €303.9K | €1.0M |
| Other Comprehensive Income | €11.0M | €0 |
| Other Noncurrent Financial Assets | €0 | €150.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €9.6K | €0 |
| Retained Earnings | €1.3M | €843.1K |
| Revaluation Increase Decrease Intangible Assets Other Than Goodwill | -€16.9M | €0 |
| Revaluation Surplus | €16.8M | €5.9M |
Every line item above is a fact tagged in BROWN'S PHARMA HOLDINGS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.